title: [Anti-diabetics and chronic kidney disease].
abstract: Diabetes mellitus (DM) is the most important non-communicable disease after hypertension. Prevalence of type 2 DM has progressively increased over the last decades. In Italy, 11.8% of the general adult population can be identified as diabetic. The major complication of DM is diabetic nephropathy (DM-CKD), which develops in approximately one-third of diabetics. Achieving optimal glycemic control is the first therapeutic goal in the management of DM-CKD. In recent years, new antidiabetic drugs have been marketed (GLP1 analogues, DPP-4 inhibitors, SGLT-2 inhibitors) to ameliorate glycemia in patients nave or treated by means of traditional agents, such as sulfonylureas, metformin, glinides, insulin. However, use of these drugs in DM-CKD should be evaluated carefully, mainly because of the higher risk of hypoglycemia that requires dosing adjustments. Metformin still represents an adequate choice if proper dose adjustments are made on the basis of renal function. Sulfonylureas with limited renal clearance, i.e., gliquidone, glipizide and gliclazide are an alternative to metformin and more effective than repaglinide on glycemic control. Other antidiabetic agents with potential nephroprotective effects, namely DPP-4 inhibitors, incretin analogues and SGLT-2 inhibitors, may allow nephroprotective effects independent of glycemic control. Insulin remains the cornerstone of therapy when oral therapy is no longer effective.
authors.forename: Carlo
authors.initials: C
authors.lastname: Garofalo
authors.forename: Nicolangelo
authors.initials: N
authors.lastname: Iazzetta
authors.forename: Andrea
authors.initials: A
authors.lastname: Camocardi
authors.forename: Mario
authors.initials: M
authors.lastname: Pacilio
authors.forename: Carmela
authors.initials: C
authors.lastname: Iodice
authors.forename: Roberto
authors.initials: R
authors.lastname: Minutolo
authors.forename: Luca
authors.initials: L
authors.lastname: De Nicola
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Conte
mesh_terms: D001645:Biguanides / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D001645:Biguanides; D007004:Hypoglycemic Agents